2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Brandon Mahal, MD, discusses the emerging role of epigenomics in prostate cancer.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Brandon Mahal, MD, assistant professor of radiation oncology, assistant director of community outreach and engagement, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the emerging role of epigenomics in prostate cancer.
Ongoing research in the field of epigenomics has garnered significant attention in prostate cancer, says Mahal.
Developing a greater understanding of the molecular characteristics of prostate cancer may lend insight into drivers of prostate cancer and disease aggressiveness, Mahal explains.
Moreover, epigenetics may inform the influence the environment has on a patient’s genome and on disparities between patient subgroups with prostate cancer, concludes Mahal.
Related Content: